Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept with low-dose steroids in refractory Myasthenia Gravis
NCT06723548Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 4 trial of telitacicept in myasthenia gravis (MG), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06723548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06723548.